Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 248

1.

Characterization of inflammatory breast cancer: a vibrational microspectroscopy and imaging approach at the cellular and tissue level.

Mohamed HT, Untereiner V, Proult I, Ibrahim SA, Götte M, El-Shinawi M, Mohamed MM, Sockalingum GD, Brézillon S.

Analyst. 2018 Dec 3;143(24):6103-6112. doi: 10.1039/c8an01292j.

PMID:
30468236
2.

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT.

Oncogene. 2018 Nov 20. doi: 10.1038/s41388-018-0569-5. [Epub ahead of print]

PMID:
30459358
3.

Skin Diseases of the Breast and Nipple Part I: Benign and Malignant Tumors.

Waldman RA, Finch J, Grant-Kels JM, Stevenson C, Whitaker-Worth D.

J Am Acad Dermatol. 2018 Nov 16. pii: S0190-9622(18)32900-1. doi: 10.1016/j.jaad.2018.08.066. [Epub ahead of print] Review.

PMID:
30452954
4.

Smartphone-based Compression-Induced Scope with Temperature Sensor for Inflammatory Breast Cancer Screening.

Saleheen F, Goldstein J, Rajan R, Caroline D, Pascarella S, Won CH.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:4969-4972. doi: 10.1109/EMBC.2018.8513437.

PMID:
30441457
5.

Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Gudina AT, Copeland G, Soliman AS, Hirko KA.

Breast Cancer Res Treat. 2018 Nov 7. doi: 10.1007/s10549-018-5037-y. [Epub ahead of print]

PMID:
30406365
6.

Erratum: Zare, A. et al. RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. Cancers, 2018, 10, 184.

Zare A, Petrova A, Agoumi M, Armstrong H, Bigras G, Tonkin K, Wine E, Baksh S.

Cancers (Basel). 2018 Nov 7;10(11). pii: E425. doi: 10.3390/cancers10110425.

7.

Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.

Wu SG, Zhang WW, Wang J, Dong Y, Sun JY, Chen YX, He ZY.

Future Oncol. 2018 Oct 31. doi: 10.2217/fon-2018-0677. [Epub ahead of print]

PMID:
30378451
8.

Palliative Local Surgery for Locally Advanced Breast Cancer Depending on Hormone Receptor Status in Elderly Patients.

Pan H, Zhang K, Wang M, Ling L, Zhou W, Wang S.

Clin Breast Cancer. 2018 Sep 27. pii: S1526-8209(18)30510-X. doi: 10.1016/j.clbc.2018.09.007. [Epub ahead of print]

PMID:
30348592
9.

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.

Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT.

PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.

10.

Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?

Romanoff A, Zabor EC, Petruolo O, Stempel M, El-Tamer M, Morrow M, Barrio AV.

Cancer. 2018 Nov 15;124(22):4314-4321. doi: 10.1002/cncr.31757. Epub 2018 Oct 11.

PMID:
30307616
11.

The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome.

Çakar B, Sürmeli Z, Öner PG, Yelim ES, Karabulut B, Uslu R.

Eur J Breast Health. 2018 Oct 1;14(4):211-217. doi: 10.5152/ejbh.2018.4170. eCollection 2018 Oct.

12.

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

Copson E, Shaaban AM, Maishman T, Moseley PM, McKenzie H, Bradbury J, Borley A, Brzezinska M, Chan SYT, Ching J, Cutress RI, Danial I, Dall B, Kerin M, Lowery AJ, Macpherson IR, Romics L, Sawyer E, Sharmat N, Sircar T, Vidya R, Pan Y, Rea D, Jones L, Eccles DM, Berditchevski F.

Breast. 2018 Sep 15;42:133-141. doi: 10.1016/j.breast.2018.09.003. [Epub ahead of print]

PMID:
30278369
13.

Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R.

PLoS One. 2018 Sep 24;13(9):e0204372. doi: 10.1371/journal.pone.0204372. eCollection 2018.

14.

Homeoprotein DLX4 expression is increased in inflammatory breast cancer cases from an urban African-American population.

Jeong J, Naab TJ, Fernandez AI, Ongkeko MS, Makambi KH, Blancato JK.

Oncotarget. 2018 Jul 27;9(58):31253-31263. doi: 10.18632/oncotarget.25790. eCollection 2018 Jul 27.

15.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.

Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.

Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

16.

Hardness and Painful Lesion of the Breast.

Vilas-Sueiro A, González-Vilas D, Aguilera C, Monteagudo B, De Las Heras C.

Acta Dermatovenerol Croat. 2017 Dec;25(4):305-306.

PMID:
30064607
17.

Inflammatory breast cancer and chest wall disease: The oncologist perspective.

Curigliano G.

Eur J Surg Oncol. 2018 Aug;44(8):1142-1147. doi: 10.1016/j.ejso.2018.05.019. Epub 2018 May 22. Review.

PMID:
30032791
18.

Vinorelbine's anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas.

Altinoz MA, Ozpinar A, Alturfan EE, Elmaci I.

J Chemother. 2018 Jul;30(4):203-212. doi: 10.1080/1120009X.2018.1487149. Epub 2018 Jul 20.

PMID:
30025492
19.
20.

Role of Operative Management in Stage IV Breast Cancer.

Teshome M.

Surg Clin North Am. 2018 Aug;98(4):859-868. doi: 10.1016/j.suc.2018.03.012. Review.

PMID:
30005779

Supplemental Content

Loading ...
Support Center